FXS0683 / Fosun Pharma - LARVOL DELTA

FXS0683-001: Phase I Study of FXS0683 in the Treatment of Blood Tumors (clinicaltrials.gov) - P1 | N=228 | Not yet recruiting | Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

First-in-human • New P1 trial • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology

In the field of prospective layout of early-stage pipeline, several new molecules have been approved for the clinical trials (The Manila Times) - "FXS0683, a next-generation Bcl-2 inhibitor, was approved for Phase I clinical trials in hematological malignancies. Innovative molecule including HLX97 (a KAT6A/B small molecule inhibitor) and HLX3901 (tetra specific antibody of DLL3×DLL3×CD3×CD28) were approved for clinical trials, widely covering refractory solid tumors such as breast cancer and small cell lung cancer."

New trial • Breast Cancer • Hematological Malignancies • Neuroendocrine Carcinoma • Small Cell Lung Cancer